New clinical trial for Trillium. Good Luck!
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
TORONTO, ONTARIO--(Marketwired - Aug 17, 2016) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration (FDA) has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI-621 (SIRPaFc), in solid tumors and mycosis fungoides.
Join in on the conversation with Andrew Haller when you subscribe to Toronto Health.